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Abstract  
Background and Aim: Given the high global prevalence of non-alcoholic fatty liver disease (NAFLD), 
the need for relevant non-invasive biomarkers and algorithms to accurately stage disease severity is 
a critical unmet medical need. Identifying those with advanced fibrosis (≥F3) is the most crucial, as 
these individuals have the greatest risk of adverse, long-term, liver-related outcomes. We aimed to 
investigate the role of PRO-C3 (a marker of type III collagen formation) as a biomarker for advanced 
fibrosis in NAFLD. Methods: We measured PRO-C3 by enzyme-linked immunosorbent assay (ELISA) 
in two large independent cohorts with extensive clinical phenotyping and liver biopsy; 150 in the 
derivation and 281 in the validation cohort. A PRO-C3 based fibrosis algorithm that included Age, 
presence of DiAbetes, PRO-C3 (a marker of type III collagen formation), and plaTelet count 
(“ADAPT”) was developed. Results: PRO-C3 increased with fibrosis stage (rho 0.50 p<0.0001) and 
was independently associated with advanced fibrosis (OR=1.05, 95% CI 1.02-1.08, p= 0.003). ADAPT 
showed areas under the receiver operating characteristics curve (AUROC) of 0.86 (95% CI 0.79 to 
0.91) in the derivation and 0.87 in the validation cohort (95% CI 0.83 to 0.91) for advanced fibrosis. 
This was superior to the existing fibrosis scores, aspartate aminotransferase (AST) to platelet ratio 
index (APRI), FIB-4 and NAFLD fibrosis score (NFS) in most comparisons. Conclusion: PRO-C3 is an 
independent predictor of fibrosis stage in NAFLD. A PRO-C3 based score (ADAPT) accurately 
identifies patients with NAFLD and advanced fibrosis and is superior to APRI, FIB-4 and NFS. 
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Introduction 
The increase in global prevalence of metabolic syndrome (MS) has been accompanied by a rise in 
organ damage including end stage disease related to non-alcoholic fatty liver disease (NAFLD). 
Estimates place the worldwide prevalence of NAFLD at 25% 1. A subset of these patients develop 
non-alcoholic steatohepatitis (NASH) that can progress to cirrhosis and are at a high risk of adverse 
liver-related outcomes1. From a management and therapeutic perspective, an unmet clinical need is 
the requirement to distinguish those with early disease from those at highest risk of clinical 
complications. While metabolic hepatic inflammation is the milieu that drives disease progression, 
various studies (including meta analyses) that have examined for prognostic histological features 
suggest that fibrosis stage is the parameter that best associates with overall- and liver-related 
mortality, as well as liver transplantation and liver related events2–5.  
The gold standard for the evaluation of liver fibrosis stage is percutaneous needle biopsy, which is 
compromised by inherent sampling and inter-observer biases and peri-procedural risk6,7. The 
invasiveness and costs of performing biopsies also makes it unsuitable for mass screening, for 
staging and risk stratification. The latter is important as the majority of patients with advanced 
fibrosis and even cirrhosis, are asymptomatic and often indistinguishable from those at earlier 
disease stages8,9. In this context, there is a need for surrogate markers of disease stage that can 
identify and risk stratify patients with NAFLD. This area of research can broadly be divided into liquid 
(typically blood based) or physical approaches (measurement of liver stiffness). Physical approaches 
while promising are less useful for population level screening and are limited by cost and other 
technique-specific considerations. Several serum based biomarker tests have previously been 
developed and applied to NAFLD patients10–14. These scores typically combine clinical features and 
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routine laboratory tests and are used primarily to rule out advanced fibrosis15, however they lack 
sufficient diagnostic accuracy and sensitivity.  
Liver fibrosis is characterized by the accumulation of excess extracellular matrix (ECM) and hence 
biomarkers reflecting structural changes occurring in the hepatic ECM during chronic injury may be 
of value in the assessment of fibrosis progression or regression. We recently demonstrated that 
PRO-C3, an ADAMTS generated neo-epitope marker of type III collagen formation, is a marker of 
fibrosis in patients with chronic hepatitis C. The role of PRO-C3 in patients with NAFLD however, is 
largely unknown. Since the performance of biomarkers and non-invasive liver fibrosis scores varies 
widely according to disease etiology, whether PRO-C3 has a role as a biomarker in NAFLD is unclear. 
In this study, we sought to a) explore the association of PRO-C3 with liver fibrosis in two large 
independent biopsy-proven cohorts with NAFLD and b) determine if PRO-C3 can be combined with 
simple and routinely available clinical variables in to a novel score for the prediction of advanced 
fibrosis in patients with NAFLD. We compared the performance of our derived model with other 
known biomarker algorithms. 
 
 Materials and Methods 
Study population 
A total of 431 well phenotyped patients with biopsy confirmed NAFLD comprised the study cohort. 
The derivation cohort included 150 patients from the Storr Liver Centre, Sydney, Australia; the 
validation cohort comprised 281 patients recruited from four international sites, Nottingham 
University Hospitals NHS Trust, United Kingdom (n=42); Kurume University School of Medicine, 
Kurume, Japan (n=48); University of Western Australia, Nedlands, Australia (n=144) and 47 
additional patients from the Storr Liver Centre.  
All patients were referred for the investigation of abnormal liver tests or steatosis detected by 
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ultrasound. The diagnosis of NAFLD was established by liver biopsy in all cases. Patients with disease 
of other etiologies including viral hepatitis and auto-immune liver disease were excluded by 
standard clinical, laboratory and histopathological assessments. Patients with evidence of hepatic 
decompensation, secondary causes of steatosis, including excess alcohol (men, >30 g/day; women, 
>20 g/day), total parenteral nutrition or the use of drugs known to precipitate steatosis were 
excluded.  
Demographic and clinical data were obtained, including age, gender, ethnicity, height, weight, and 
waist circumference at the time of biopsy. Body mass index (BMI) was calculated as BMI = kg/m2. 
Arterial hypertension was defined as blood pressure ≥130/≥85 mmHg or treatment with 
antihypertensive drugs. Diabetes was defined as a fasting blood glucose ≥7.0 mmol/L, previous 
diagnosis of diabetes or use of anti-diabetic drugs. Hyperlipidemia was defined as fasting total 
cholesterol >5.5 mmol/L, triglycerides >1.7 mmol/L or treatment with lipid-lowering drugs. Ethical 
approval and written informed consent from patients was obtained from all participating centers.  
Histology  
All biopsies were routinely stained with hematoxylin & eosin and Masson’s Trichrome. The stained 
sections were read and scored by an expert liver pathologist at each participating center using the 
scoring system proposed by Kleiner et al., 200516. The stage of liver fibrosis was defined as: stage 0, 
absence of fibrosis; stage 1, perisinusoidal or portal fibrosis; stage 2 perisinusoidal and 
portal/periportal fibrosis; stage 3 septal or bridging fibrosis; and stage 4 as cirrhosis. A diagnosis of 
NASH was according to the EASL-EASD-EASO guidelines.17 Thirty-one biopsies were scored 
independently by pathologists from the various centers, and inter observer agreement was 
calculated using the κ statistic and was =0.55 for fibrosis, comparable to previously published 
results18–21.  
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Biomarker quantification 
At the time of biopsy, a fasting blood sample was obtained and routine biochemical tests were 
performed using standard methods and assays. Biochemical tests included albumin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, gamma-
glutamyltransferase (GGT), insulin, high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
platelets, and triglycerides.  Additional blood samples were drawn and frozen at −80°C for future 
research. Type III collagen formation was assessed in serum using the PRO-C3 competitive ELISA 
assay from Nordic Bioscience, Herlev, Denmark, as previously described22.  
The APRI, FIB-4 and NAFLD Fibrosis Scores were calculated using clinical and routine laboratory 
variables and previously defined algorithms and cut-off values for NAFLD/NASH patients10,12,14,23.  
Statistical analysis 
The main aim of this study was the development of an algorithm comprised of clinical and laboratory 
variables that could accurately distinguish patients with advanced fibrosis (F≥3) from those without. 
To this end, patients in the derivation cohort were stratified into those with advanced fibrosis (F≥3) 
and those without (F0-2). Stage 2 and 3 for lobular and portal inflammation was pooled as only 1 
patient in both groups was graded stage 3. Continuous variables in the two groups were compared 
using the t test and categorical variables were compared using Fisher’s exact test. Comparisons 
between mean marker levels were performed using the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test. Variables that were significantly different between patients with advanced 
fibrosis and those without advanced fibrosis were identified as potential algorithm components.  
For the formulation of predictive models, variables showing a p <0.05 at univariate analysis (Student 
t test for parametric variables, and X2 or Fisher exact test for frequencies) were included. The 
interaction between these variables was first tested. Variables explaining a statistically significant 
proportion of the variance (p <0.05) were maintained in the model using the likelihood ratio (LR) 
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test. The model variables were selected using the leave-one-out method to facilitate the calculation 
of over-fit bias reduced estimates24. To avoid over-fitting, 10-fold cross validations were used in the 
tree building process. 
The model was as following: 
ܣܦܣܲܶ = ݁ݔ݌ቆ݈݋݃	ଵ଴ ൬
ܣ݃݁	 × 	ܴܱܲ⎯ܥ3
√݈ܲܽݐ݈݁݁ݐݏ ൰ቇ + ܦܾ݅ܽ݁ݐ݁ݏ 
The discriminative ability of the model for the identification of severe fibrosis (F≥3) was assessed by 
means of receiver operating characteristic curve analysis and expressed as area under the receiver 
operating characteristic curve (AUROC). A cut-off value to distinguish patients with advanced fibrosis 
from those without was determined using the bootstrap Youden Index. The diagnostic accuracy of 
the algorithm and the derived cut-off was determined by calculating sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV). To overcome both spectrum effect and 
ordinal scale issues, we undertook two approaches. Firstly, we used the Obuchowski measure, as 
proposed by Lambert et al25,26, which is a measure of the probability that two randomly chosen 
patients from different fibrosis stages are correctly classified according to the weighted scheme, 
with a penalty for incorrect classification. In the second method, we standardized the AUROC for the 
distribution of fibrosis stages as proposed by Poynard et al27, as recently described28. 
ROC curves were also calculated for the established diagnostic scores, APRI, FIB-4 and NAFLD 
Fibrosis Score. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
positive and negative likelihood ratio (LHR+, LHR−) and 95% CIs were calculated. Estimates of AUROCs 
and comparisons between AUROCs were performed using the method suggested by Hanley and 
McNeil29. Validation was subsequently performed on the validation cohort as well as for the 
combined overall cohort.  
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All data are shown as medians and variation expressed via Tukey plots. P-values <5% were 
considered significant. Model building and statistical analysis was performed using MedCalc version 
16.8.4 (MedCalc Software, Ostend, Belgium) and SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). 
Graphs were designed using GraphPad Prism version 7 (GraphPad Software, Inc., CA, USA).  
 
Results 
Patient Characteristics 
The characteristics of the 150 NAFLD patients used to develop the model (derivation cohort) and the 
281 used to test the model (validation cohort) are shown in Table 1. Serum levels of albumin, AST, 
cholesterol and HDL were all significantly lower in the validation cohort when compared to the 
derivation cohort. In addition, both BMI and insulin level were found to be significantly elevated. No 
other significant differences were observed between the two cohorts. The prevalence of severe 
fibrosis was not significantly different between the cohorts. 
PRO-C3 is highly associated with severity of fibrosis and histological parameters 
Within the derivation cohort, a neo-epitope marker of type III collagen formation, PRO-C3, was 
found to be significantly elevated in patients with advanced fibrosis (F≥3) compared to the 
mild/moderate group (p<0.0001). PRO-C3 was highly associated with disease severity (Figure 1) and 
moderately correlated to the severity of fibrosis (rho = 0.501, p<0.0001). PRO-C3 was able to 
discriminate between the following stages of fibrosis (Figure 1): F0 versus F2 (27% increase, 
p<0.0332), F0 versus F3 (54% increase, p<0.0001), F1 versus F3 (36% increase, p<0.0002) and F0 
versus F4 (57% increase, p<0.0021). In addition, PRO-C3 discriminated between the various stages of 
hepatocyte ballooning (stage 0 versus stage 1 p=0.001, stage 0 versus 2 p=0.0003), lobular 
inflammation (stage 0 versus stage 1 p=0.0004, stage 0 versus stage 2 and 3 p=0.0008) and steatosis 
(stage 1 versus stage 3 p=0.003).  
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We undertook logistic regression to discern the effect of various clinical variables on the association 
of PRO-C3 with the presence of advanced fibrosis (F≥3) within the derivation cohort. In this analysis, 
PRO-C3, when adjusted for age, ALT, AST, BMI, ballooning, lobular inflammation, presence of 
diabetes, GGT and platelet count, was independently associated with advanced fibrosis (OR=1.054, 
95% CI 1.01-1.07) (Table 2). The area under the receiver-operating curve (AUROC) for the 
identification of patients with advanced fibrosis (F≥3) of PRO-C3 alone was 0.81 (95% CI 0.74-0.87) 
(Data not shown).  
Clinical parameters associated with the level of PRO-C3 
Given that univariate and multivariate analyses revealed that the level of PRO-C3 was a strong 
predictor of advanced fibrosis, we examined for clinical parameters associated with the level of PRO-
C3. It was subsequently found that ALT (rho 0.29, p=0.0004), AST (rho 0.42, p<0.0001), fasting blood 
glucose (rho 0.23, p=0.007), insulin level (rho 0.43, p<0.0001), platelet count (rho -0.24, p=0.004) 
and presence of diabetes (rho 0.16, p=0.05) all correlated with the level of PRO-C3 to varying 
degrees.  
Development of a PRO-C3 based predictive fibrosis score (ADAPT) 
Based on the finding that PRO-C3 is strongly associated with fibrosis, we sought to build a model for 
the prediction of significant fibrosis based on PRO-C3 and routinely assessed clinical and laboratory 
variables. Patients within the derivation cohort were divided into two groups according to NASH CRN 
fibrosis stage, F0-2 (no fibrosis to moderate fibrosis) and F3-4 (advanced fibrosis) (Table 3). PRO-C3 
was elevated in patients with advanced fibrosis compared to the mild to moderate group 
(p<0.0001). Furthermore, those with advanced fibrosis had significantly increased levels of AST, GGT 
and a higher AST/ALT ratio (Table 3). As would be expected, patients with advanced fibrosis had a 
worse metabolic profile with lower LDL, higher circulating insulin levels and a higher waist-to-hip 
ratio (Table 3). The presence of diabetes was more likely in patients with advanced fibrosis; 67% of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
patients with F3-4 had diabetes compared to just 29% of the F0-2 group (p=0.002) (Table 3). In 
addition, patients with advanced fibrosis were found to be older (p=0.02) and with a lower platelet 
count compared to those without (p=0.002) (Table 3).  
Variables that were significantly different between the two groups (p<0.05) were considered eligible 
for the model building process. Those that described a statistically significant proportion of the 
variance were included in the model using the likelihood ratio (LR) test. Ultimately, the variables that 
were included within the model, named “ADAPT”, were age, presence of diabetes, platelet count 
and PRO-C3. 
The diagnostic capability of the ADAPT score was assessed via AUROC and was higher than that of 
PRO-C3 alone, yielding an AUROC of 0.86 (95% CI 0.79-0.91) (Figure 2).  
Validation of the diagnostic capabilities of the ADAPT score 
To ascertain the validity of our model, the ability of ADAPT to identify patients with advanced 
fibrosis was corroborated in a separate cohort comprised of patients from four centers across Asia-
Pacific and Europe (n=281). Several significant differences were identified between the derivation 
and the validation cohort; these differences reflect the heterogeneity of NAFLD patients with 
advanced fibrosis. Despite cohort differences, the diagnostic accuracy of ADAPT was maintained 
with an AUROC in the validation cohort of 0.87 (95% CI 0.83-0.91) (Figure 3).  
The diagnostic performance of a score, when assessed by AUROC, may vary according to disease 
prevalence, known as spectrum bias30. The Obuchowski measure accounts for the spectrum bias and 
provides a means by which the diagnostic accuracy of a score can be assessed. The Obuchowski 
measure of ADAPT within the derivation cohort was calculated to be 0.86 and within the validation 
cohort it was 0.89. Additionally, we standardized the AUROC for the distribution of fibrosis stages 
according to Poynard et al27. The standardized AUROC of ADAPT was found to be 0.89 and 0.89 
within the derivation and validation cohorts, respectively (Table 4). For further confirmation of the 
generalizability of the model, the validation cohort was stratified into various groups according to 
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age, (<50, 50-60 and >60), BMI, Sex, NASH vs NAFL and center. In this analysis, ADAPT remained a 
robust algorithm in that the AUROC was maintained across all sub-populations, with NPV 
consistently exceeding 90% (Supplementary Figure 1).  
Performance of ADAPT against standard algorithms 
Within the derivation cohort the AUROC of “ADAPT” (AUROC=0.855) was superior to clinically 
available serum based non-invasive scores: APRI (AUROC=0.73, p=0.02), FIB-4 (AUROC=0.78, p=0.06) 
and NAFLD Fibrosis Score (AUROC=0.78, p=0.06) (Table 4). Likewise, in the validation cohort, the 
AUROC of “ADAPT” (AUROC=0.87) was greater than APRI (AUROC=0.78, p=0.0005), FIB-4 
(AUROC=0.85, p=0.32) and NAFLD Fibrosis Score (AUROC= 0.79, p=0.02) (Table 4). Adjusting the 
AUROC according to Poynard et al27 caused minor increases in the AUROC in all scores (Table 4). 
Further investigation into the ability of ADAPT to identify patients with clinically significant fibrosis 
(F2-F4) highlighted the superiority of the ADAPT score when compared to other clinically available 
serum based non-invasive scores (supplementary table 3). 
Derivation of cut-off values  
The derivation cohort was subjected to ROC curve analysis to derive a cut-off value for the rule-in 
and rule-out of advanced fibrosis. A value of >6.3287 for the rule in/out of advanced fibrosis was 
identified by the Youden Index, PPV 48.4%, NPV 96.6%, (Supplementary table 2). By applying this 
cut-off, 73% (n=158) F0-2 patients were correctly classified and 27% (n=58) incorrectly classified. 
Among F3-4 patients, 92% (n=60) were correctly classified while 8% (n=5) were incorrectly classified 
(Table 5). We applied previously derived cut-off values for APRI (rule in advanced fibrosis >1.5, rule 
out advanced fibrosis <0.5), FIB-4 (rule in advanced fibrosis >2.67, rule out advanced fibrosis <1.3) 
and NAFLD Fibrosis Score (rule in advanced fibrosis >0.676, rule out advanced fibrosis <-1.455)10,14,23. 
A large proportion of patients fell within an indeterminate zone, table 5. FIB-4 and APRI showed 
reasonable performance at identifying patients without advanced liver fibrosis, 68% (n=147) and 
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67% (n=145) were correctly classified, respectively. However, these scores performed poorly at 
identifying patients with advanced liver fibrosis, NAFLD Fibrosis Score and FIB-4 correctly identified 
51% (n=33) and 46% (n=30) patients, respectively. 
 
Discussion 
In this study, we measured PRO-C3 in NAFLD patients from centers across the world and with a wide 
variation in ages and clinical manifestations, similar to that observed in daily clinical practice. The 
principal findings were that: 1) PRO-C3 progressively increases with fibrosis severity in NAFLD but 
that the association remains highly significant even after adjustment for multiple biochemical and 
clinical parameters, and 2) PRO-C3 when combined with routine clinical parameters (ADAPT) 
generated a highly accurate tool for the detection of advanced fibrosis in NAFLD. ADAPT is thus a 
unique score that has utility for risk stratification and for the clinical management of patients with 
non-alcoholic fatty liver disease.  
Non-invasive biomarkers that reflect the process of hepatic fibrosis are urgently needed; collagen 
formation biomarkers are thus attractive targets. Here we demonstrate that PRO-C3, which 
measures type III collagen synthesis is a novel and precise marker for advanced liver fibrosis in 
concordance with what we have recently shown in chronic hepatitis C22,31,32. Notably, a recent small 
non-biopsy study (n=297) from a phase III study of balaglitazone in patients with late-stage Type 2 
diabetes (BALLET study) suggested that PRO-C3 could have utility as a determinant of treatment 
response to a potential anti-fibrotic therapy33. Karsdal et al (2016) subsequently confirmed this 
within a study investigating the anti-fibrotic efficacy of farglitazar33; Harrison et al (2018) further 
explored PRO-C3 as a determinant of treatment response within a phase IIb study34. Though that 
finding needs to be validated in biopsy proven cohorts, their data in combination with our findings 
suggest that PRO-C3 could serve as a biomarker not only for prediction of fibrosis progression, but 
also for treatment response. Interestingly, the optimal cut off value in our study was 15.6 ng/ml for 
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advanced fibrosis, which is significantly different from that in patients with hepatitis C (20 ng/ml)35. 
Consistently, the cut off level for PRO-C3 was also lower in the BALLET report (13.1 ng/ml)33. Further 
studies will be required to confirm the optimal cut off in NAFLD. It is noteworthy that the levels of 
PRO-C3 did not increase from F3 to F4. The explanation for this finding is not clear and further 
mechanistic studies are required. 
Previous reports have suggested that the pro-peptide of type III collagen22,36 can be used as a 
biomarker for NASH. However, we have shown that PRO-C3 is distinct from PIIINP in that it is a true 
marker of type III collagen formation and by extension, fibrogenesis22. We subsequently developed a 
novel PRO-C3-based fibrosis score for NAFLD patients and compared it to various composite serum 
based score systems that have been proposed and tested in NAFLD patients, namely APRI, FIB-4 and 
the NAFLD Fibrosis Score. The AUROCs for the various scores examined in this study, all performed 
similar to previous reports for the identification of advanced fibrosis27,37–39. In contrast, ADAPT was 
superior, as also in the multi-national validation cohort. Critically, ADAPT was robust at identifying 
patients with advanced fibrosis across different subpopulations (diabetics vs non-diabetics, NAFL vs 
NASH, various age ranges and BMI categories), some of which have been shown to confound non-
invasive algorithms40,41. The AUROC of ADAPT was maintained at >0.80 for all subpopulations, while 
the PPV and NPV remained consistent. From a management perspective, after the application of a 
derived cut-off value, ADAPT correctly classified 74% of patients without advanced fibrosis and 92% 
with advanced fibrosis. Cut-off values for APRI, FIB-4 and NAFLD Fibrosis Score were applied to our 
patients; similar to previous reports, we found that a large proportion of patients fell within an 
indeterminate zone 37. FIB-4 and APRI showed reasonable performance at identifying patients 
without advanced fibrosis, but performed poorly at identifying patients with advanced fibrosis. 
Furthermore, the superiority of ADAPT is exemplified by its robust performance across various sub-
populations (supplementary table 1) and by the substantially higher NPV. In contrast, the 
performance of FIB-4 has been demonstrated to be variable and is affected by confounders such as 
age. Additionally, unlike FIB-4, ADAPT is unburdened by the presence of an intermediate zone, which 
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hinders its accuracy37,41–44. An advantage of PRO-C3 used alone or in combination as in ADAPT, is that 
it may stratify cirrhosis since the score is on a spectrum. This contrasts with FIB-4 or the NAFLD 
fibrosis score which are based on a dichotomous threshold. Hence, PRO-C3 based scores may have 
potential in patient monitoring over time, though this needs validation. 
In contrast to the other non-invasive scores, ADAPT is distinct in that it combines PRO-C3 with 
important clinical and metabolic parameters associated with disease severity. Both increased age 
and the presence of diabetes are well-established risk factors for progressive liver disease and are 
easily discerned45. Similarly, platelet count is routinely measured and is strongly correlated with liver 
fibrosis and has been incorporated into multiple other non-invasive scoring systems10,12,14. A study by 
Mofrad et al has shown that the full spectrum of liver fibrosis stages can be found in patients 
presenting with liver enzymes in the normal range8. In addition, liver enzymes are sensitive to age 
leading to false positive results. Thus, previous analysis has shown that FIB-4 (and likely also APRI 
and the NAFLD fibrosis score) cannot be universally applied without modification to all patient 
groups41. The lack of inclusion of liver enzymes in ADAPT is thus a conspicuous advantage. 
Non-invasive tests have been proposed as screening tools for detecting advanced liver fibrosis in the 
general population, where the prevalence of this outcome is low46. Score systems such as ADAPT, 
that exhibit a high specificity and NPV could provide a useful tool for clinicians as they reduce any 
uncertainty surrounding the diagnosis and the number of follow-up assessments required46. We 
propose that the ADAPT score could be used as such a screening tool within the general population 
to identify patients at risk of or with advanced fibrosis, such that interventions could be applied and 
progression to cirrhosis perhaps mitigated. However, further validation in non-referral cohorts and 
demonstration of the cost-effectiveness of using PRO-C3 based score systems is first required.  
Our study has some limitations that must be acknowledged. We included well-characterized 
biopsied patients from centers with an interest in studying NAFLD, therefore referral bias cannot be 
ruled out. Biopsies were read by an independent pathologist at each participating center using a 
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well-defined and standardized score system. In our hands, the kappa value for assessing the severity 
of fibrosis has previously been shown to be good47. As previously described by Ratziu et al, liver 
biopsy as a diagnostic tool has several limitations including sampling bias6. However, all non-invasive 
diagnostic tools for fibrosis assessment are benchmarked against the biopsy. Thus, the use of an 
imperfect reference standard may result in underperformance of the accuracy of non-invasive 
scores. Additionally, due to the nature of this cross-sectional study, we could not follow the clinical 
progress of patients; it would be of interest to investigate the relationship of score classification with 
patient outcome.  
In conclusion, a biomarker score based on PRO-C3 and clinical variables (ADAPT) accurately predicts 
the presence or absence of advanced fibrosis in a NAFLD population. Thus, ADAPT could be useful 
for risk stratification and management. Further independent studies will be required to determine 
whether patients stratification using ADAPT followed by measurement of liver stiffness can replace 
the need for liver biopsy as a diagnostic standard in NAFLD. 
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 Table 1. Characteristics of the total patient population  
 Derivation Cohort Validation Cohort Derivation cohort 
vs Validation cohort
 n Mean SD n Mean SD P-value 
Age (Years) 150 50.85 12.13 277 52.9 12.38 ns 
Albumin (g/dL) 148 4.403 5.54 277 4.07 0.40 <0.0001 
ALT (IU/L) 148 77.01 50.48 278 69.58 58.43 ns 
AST (IU/L) 149 55.02 35.42 262 46.45 33.40 0.02 
AST/ALT 148 0.79 0.34 220 0.76 0.38 ns 
BMI (kg/m2) 145 31.3 5.38 274 34.98 9.54 <0.0001 
Cholesterol (mmol/L) 148 5.21 1.21 198 4.7 1.15 0.0001 
Diabetic 150 37.3% 281 37.4% ns 
Insulin (mIU/L) 147 17.46 12.7 148 26.37 31.81 0.002 
FBS (mmol/L) 145 6.46 3.10 239 6.54 2.72 ns 
Fibrosis Score 
(0/1/2/3/4) 
42/48/27/25/8 90/87/37/44/21 ns 
Gender (% Female) 150 50.7 281 58 ns 
GGT (IU/L) 148 128 141 256 112.57 160.24 ns 
HDL (mmol/L) 143 1.26 0.41 212 1.2 0.35 0.03 
LDL (mmol/L) 140 3.07 0.99 179 2.78 1.56 ns 
NASH 55  127 ns 
Platelets (×109/L) 148 244.4 73.53 270 229.7 79.49 ns 
PRO-C3 (ng/mL) 150 20.92 15.48 279 19.93 18.04 ns 
Triglycerides (mmol/L) 149 2.03 1.60 263 1.97 1.40 ns 
Waist/Hip ratio 136 0.97 0.08 41 0.97 0.09 ns 
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Table 2 Multivariate logistic regression analyses 
 Presence of Advanced Fibrosis
PRO-C3 Adjusted for  OR (95% CI) P-value
Unadjusted 1.06 (1.03 to 1.09) 0.0003
Age 1.06 (1.03 to 1.09) 0.0003
ALT 1.07 (1.03 to 1.10) 0.0008
AST 1.05 (1.02 to 1.09) 0.0032
Ballooning 1.05 (1.02 to 1.08) 0.0015
BMI  1.06 (1.02 to 1.09) 0.0004
Diabetes  1.06 (1.03 to 1.09) 0.0002
Gender 1.06 (1.03 to 1.09) 0.0003
GGT 1.05 (1.01 to 1.08) 0.0044
Lobular inflammation 1.05 (1.02 to 1.08) 0.0008
Platelets  1.05 (1.02 to 1.09) 0.0019
Fully Adjusted 1.04 (1.01 to 1.07) 0.0078
Unadjusted and adjusted odds ratios (OR) with 95% confidence intervals (CI) for the increase in PRO-
C3 
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Table 3 Predictors of Advanced Fibrosis 
 
F=0-2 F=3-4
 
 
n Mean SD n Mean SD P 
a
 
Age (Years) 117 49.60 12.28 33 55.30 10.60 0.02 
ALT (IU/L) 116 74.31 45.10 32 86.81 66.44 ns 
AST (IU/L) 117 51.92 33.30 32 66.34 40.87 0.04 
AST/ALT Ratio 116 0.76 0.31 32 0.91 0.39 0.03 
BMI (kg/m2) 113 30.99 5.46 32 32.37 4.98 ns 
Diabetes 29%  67% 0.0002b 
FBSL (mmol/L) 114 6.49 3.38 31 6.37 1.70 ns 
GGT (IU/L) 116 111.53 124.14 32 187.78 180.08 0.006 
HDL (mmol/L) 114 1.26 0.38 29 1.29 0.49 ns 
Insulin (mIU/L) 115 15.37 10.58 31 25.74 16.25 <0.0001 
LDL (mmol/L) 112 3.19 0.96 28 2.57 0.96 0.002 
Platelets (×109/L) 115 254.17 66.14 33 210.45 87.89 0.002 
PRO-C3 (ng/mL) 117 17.87 13.10 33 31.72 18.42 <0.0001 
TG (mmol/L) 117 2.03 1.61 32 2.03 1.60 ns 
Total cholesterol (mmol/l) 116 5.29 1.12 32 4.89 1.46 ns 
Waist\Hip ratio 106 0.96 0.08 30 1.01 0.06 0.001 
Univariate analysis of variables to identify potential predictors of advanced fibrosis. 
a
 T-test was 
assessed to test for significant differences within continuous variables and b Fisher’s exact test 
was used for categorical variables 
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Table 4 
  Derivation Cohort Validation Cohort 
Non-invasive test AUROC AdjAUROCSD 95% CI AUROC AdjAUROC SD 95% CI 
APRI 0.73 0.76 0.05 0.65 to 0.80 0.78 0.80 0.03 0.73 to 0.83
FIB-4 0.78 0.81 0.05 0.70 to 0.84 0.85 0.87 0.02 0.80 to 0.89 
NAFLD Fibrosis Score 0.78 0.82 0.05 0.71 to 0.85 0.79 0.81 0.03 0.74 to 0.84
PRO-C3 0.81 0.85 0.04 0.74 to 0.87 0.83 0.84 0.03 0.78 to 0.87
ADAPT 0.86 0.89 0.04 0.79 to 0.91 0.87 0.89 0.02 0.83 to 0.91 
AUROC-area under the receiver operating curve, SD- standard deviation, 95% CI- 95% confidence intervals
AdjAUROC- AUROC that has been adjusted according to the Poynard et al  
 
 
 
 
Table 5 
F0-2 F3-4
Correctly
Identified Indeterminate 
Incorrectly
Identified 
Correctly
Identified Indeterminate 
Incorrectly 
Identified 
∑ 216 65
APRI 145 63 8 10 36 19 
FIB-4 147 54 15 30 25 10 
NFS 91 100 25 33 25 7 
ADAPT 158 - 58 60 - 5 
Number of patients correctly, incorrectly or indeterminately classified by the various non-
invasive scores 
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